全文获取类型
收费全文 | 1482篇 |
免费 | 375篇 |
国内免费 | 89篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 80篇 |
妇产科学 | 16篇 |
基础医学 | 32篇 |
口腔科学 | 5篇 |
临床医学 | 300篇 |
内科学 | 352篇 |
皮肤病学 | 123篇 |
神经病学 | 245篇 |
特种医学 | 68篇 |
外科学 | 475篇 |
预防医学 | 129篇 |
眼科学 | 2篇 |
药学 | 19篇 |
肿瘤学 | 82篇 |
出版年
2023年 | 30篇 |
2022年 | 5篇 |
2021年 | 30篇 |
2020年 | 45篇 |
2019年 | 17篇 |
2018年 | 93篇 |
2017年 | 85篇 |
2016年 | 88篇 |
2015年 | 97篇 |
2014年 | 168篇 |
2013年 | 156篇 |
2012年 | 52篇 |
2011年 | 66篇 |
2010年 | 109篇 |
2009年 | 151篇 |
2008年 | 93篇 |
2007年 | 42篇 |
2006年 | 49篇 |
2005年 | 34篇 |
2004年 | 18篇 |
2003年 | 23篇 |
2002年 | 19篇 |
2001年 | 74篇 |
2000年 | 85篇 |
1999年 | 49篇 |
1998年 | 39篇 |
1997年 | 60篇 |
1996年 | 51篇 |
1995年 | 41篇 |
1994年 | 20篇 |
1993年 | 12篇 |
1992年 | 11篇 |
1991年 | 16篇 |
1990年 | 11篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1986年 | 1篇 |
1985年 | 1篇 |
排序方式: 共有1946条查询结果,搜索用时 50 毫秒
1.
2.
Shahid Ahmed MD PhD FRCPC Sukanya Pati MD Duc Le MD MSc FRCPC Kamal Haider MD Nayyar Iqbal MD FRCP 《Journal of surgical oncology》2020,122(2):144-154
Over the past two decades, gene expression profiling of breast cancer has emerged as an important tool in early-stage breast cancer management. The approach provides important information on underlying biological mechanisms, breast cancer classification, future risk potential of developing recurrent metastatic disease, and provides beneficial clues for adjuvant chemotherapy in hormone receptor (HR) positive breast cancer. Of the commercially available genomic tests for breast cancer, the prognostic and predictive value of 21-gene recurrence score tests have been validated using both retrospective data and prospective clinical trials. In this paper, we reviewed the current evidence on 21-gene expression profiles for HR-positive HER2-negative early-stage breast cancer management. We show that current evidence supports endocrine therapy alone as an appropriate adjuvant systemic therapy for approximately 70% of women with HR-positive, HER2-negative, node-negative breast cancer. Evolving evidence also suggests that 21-gene recurrence scores have predictive values for node-positive breast cancer and that chemotherapy can be avoided in more than half of women with nodes 1 to 3 positive HR-positive breast cancer. Furthermore, retrospective data also supports the predictive role of 21-gene recurrence scores for adjuvant radiation therapy. A prospective trial in this area is ongoing. 相似文献
3.
4.
Raffit Hassan MD Christine Alewine MD PhD Idrees Mian MD Anna Spreafico MD PhD Lillian L. Siu MD FRCPC Carlos Gomez-Roca MD Jean-Pierre Delord MD PhD Antoine Italiano MD PhD Ulrik Lassen MD PhD Jean-Charles Soria MD PhD Rastilav Bahleda MD Anish Thomas MBBS MD Seth M. Steinberg PhD Cody J. Peer PhD William D. Figg PharmD Gerhard Niederfellner PhD Valérie Méresse Naegelen MD Ira Pastan PhD 《Cancer》2020,126(22):4936-4947
5.
6.
7.
Andre C. Felicio MD PhD Katherine Dinelle MSc Pankaj A. Agarwal MD DNB DM Jessamyn McKenzie LPN Nicole Heffernan RN Jeremy D. Road MD Silke Appel‐Cresswell MD Zbigniew K. Wszolek MD Matthew J. Farrer PhD Michael Schulzer MD PhD Vesna Sossi PhD A. Jon Stoessl CM MD FRCPC 《Movement disorders》2014,29(9):1197-1201
8.
Background: The INCAT (Inflammatory Neuropathy Cause and Treatment) disability score is a measure of activity limitation. It is used frequently as a primary endpoint in inflammatory polyneuropathy clinical trials. A comprehensive critical analysis of its measurement properties has not been performed. Methods: Critical analysis of measurement properties. Results: The INCAT disability score was derived based on items from Guy's Neurological Disability Scale (GNDS), a disability measure intended for application in multiple sclerosis. Strengths of the INCAT score include evaluation of upper and lower limb dysfunction, ease of administration (feasibility), high face validity, and high reliability. Weaknesses of the scale include concerns about methodological quality of validation studies; failure to properly capture activity limitations due to proximal arm weakness, or fatigue; heavy individual item weighting; and poor sensitivity for detection of clinically important change. Conclusions: Although the INCAT scale has been an effective tool in inflammatory polyneuropathy studies, its limitations may warrant development of new scales. Muscle Nerve 50:164–169, 2014 相似文献
9.
Yun-Bi Ni MMSC Julia Y. S. Tsang PhD Siu Ki Chan FHKCPath Gary M. Tse FRCPC 《Annals of surgical oncology》2014,21(9):2928-2933
Background
Histologic grade, TNM stage, and Nottingham Prognostic Index are traditional prognostic tools for breast cancer. “IHC-molecular” classification of breast cancer can also identify patients at different recurrence risks and provides insight into cancer therapy. However, cancers in each group are heterogeneous. A model based on the comprehensive analysis of morphologic features and molecular subtype was constructed to predict recurrence and refine these traditional prognostic tools.Methods
Morphologic features including histologic grade, fibrotic focus, extensive intraductal component, lymphocytic infiltrate, lymphovascular invasion, tumor necrosis, tumor margin and TNM stage, and molecular subtypes approximated by immunohistochemistry were analyzed in 633 patients with invasive breast carcinoma (excluding those with HER2 targeted therapy). Significant independent predictors for recurrence included: high histologic grade (p = 0.004), presence of lymphovascular invasion (p = 0.004), fibrotic focus (p = 0.020), mild lymphocytic infiltrate (p = 0.013), high TNM stage (p < 0.001), and HER2-overexpressing (p = 0.004) and basal-like (p < 0.001) molecular subtypes. A morphologic-molecular recurrence predictive model based on these features was useful in recurrence prediction, independent of treatment modalities, and was able to refine the traditional prognostic tools of histologic grade, TNM stage, and Nottingham prognostic index, particularly for intermediate-risk groups, and to refine the luminal group molecular subtypes. Such findings were reproducible with a validation cohort.Conclusion
TNM stage, histologic grade, lymphovascular invasion, fibrotic focus, mild lymphocytic infiltrate, HER2-overexpressing and basal-like molecular subtypes were important independent recurrence risk factors for breast cancer. This morphologic-molecular model was robust in recurrence prediction and refined recurrence risk stratified by the traditional prognostic parameters, independent of treatment modalities. 相似文献10.
Maher Saqqur MD MPH FRCPC Georgios Tsivgoulis MD Francois Nicoli MD David Skoloudik MD Vijay K. Sharma MD Vincent Larrue MD Jürgen Eggers MD PhD FAHA Fabienne Perren MD Paris Charalampidis PhD Dale Storie PSL Ashfaq Shuaib MD FRCPC FAHA Andrei V. Alexandrov MD RVT 《Journal of neuroimaging》2014,24(3):209-220